Outlook 2024: CAR-T Cell Therapy
I would like to wish all my readers a happy, joyful and above all healthy new year 2024. At the beginning of a year, one is sometimes asked where one sees interesting potentials in terms
Continue readingI would like to wish all my readers a happy, joyful and above all healthy new year 2024. At the beginning of a year, one is sometimes asked where one sees interesting potentials in terms
Continue readingThe treatment options for progressive MS are limited – so interest was high when the study data on the use of high-dose biotin in progressive MS was first presented at the American Neurology Congress in
Continue readingI was pleased by the interest that my last post about the course of MS has generated – the article was shared quite often and there have not been so many comments shortly after going
Continue readingI am often asked in the consultation hour: “Do I now have a relapsing or a chronic-progressive course.” And usually, this question is posed by younger patients who have recently been diagnosed with MS. There
Continue readingAt the end of April, I had the opportunity to attend the annual meeting of the American Academy of Neurology (AAN) – the largest annual neurological congress where more than 10,000 neurologists and neuroscientists meet.
Continue readingThe news has been known since 01.12.2014, but it is still so fresh that it is worth picking up. It is known that the therapy of relapsing MS has received numerous innovations in recent years,
Continue readingUnsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.